TransCode Therapeutics, Inc. Common Stock Investor update

Hello, this is Craig Brelsford with RedChip Companies. Thank you for joining today's event with TransCode Therapeutics, which trades on the Nasdaq under the ticker RNAZ. Joining us today is Philippe Calais, Chairman and CEO of TransCode, Zdravka Medarova, Co-founder and Chief Scientific Officer, and John Tattory, the interim CFO. We will begin with a brief presentation in a moment, and then we will open the event to your questions. Welcome to everyone joining us today on X, YouTube, LinkedIn, and other social media platforms. To submit your question, we invite you to join us on Zoom. Use the link provided. Once in Zoom, click the Q&A button at the bottom of your window and type your question into the text box. Before we begin, please allow me to read the safe harbor statement.

This call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Forward-looking statements involve risks and uncertainties. Philippe, please go ahead. Great.

Thank you very much, and hello, everybody. It's a pleasure to have the opportunity to describe our company today, and let's jump in right away into the company overview. We really describe ourselves as a rare small-cap company with three near-term catalysts. First of all, we have a very strong pedigree with some Harvard founders, and Z is one of them, she will be talking later on, from Mass General and Harvard Medical School. The company was founded in 2016, became public in 2021, and has a fairly good financial profile so far with no long-term debt. We are basically pioneering approaches that are complementary and that aim at redefining the boundaries of advanced cancer. We have three key pillars there. The first of which is the RNA-targeted therapeutics that is prioritized.

We have vaccine immunotherapy product that mobilize the immune system, and then we have also immuno-oncotic agents that directly target tumors. We will focus primarily on the prioritized asset, which are the RNA therapeutics. If we look at our focus, we are targeting an area that is marked by, right now, a very strong medical need in the sense that the advanced disease in cancer is the major source of death and reducing significantly the survival of the patient. You have some graphs here highlighting in different diseases, prostate, female, colorectal, lung, and melanoma cancer, showing the 5-year relative survival that is significantly reduced as patients are moving into the advanced stages of cancer. This is not only just a major health burden for the patient, but it's also for society and also for the healthcare system. If we look at the organization, we are a small company.

We have 12 employees. All of them are experts into their own field. We are also surrounded by a very strong consulting group of experts that are basically a handful of them, that are specialized in their own area, whether this is on the clinical side, on the strategic side, or on translational science. Our board of directors is comprised of people who have demonstrated strong experience in developing and being successful with exits in the biotech sector. Our scientific advisory board is comprised of one of the co-founder who was working with Zdravka Medarova, Anna Moore. She is also the chair of the scientific advisory board. We have people like Keith Flaherty, Frank Slack, who are well-known leaders in the field of oncology. Very strong team there. If we look at our pipeline, this is a fairly busy slide.

But as I said early on, we have prioritized the lead asset that is- Hi, Philippe.

Yeah, sorry. I am terribly sorry.

I am not seeing the slides being advanced.

Oh, because I see them. Sorry. I have them advancing.

Sorry about that. How can I resolve that? I guess you see the pipeline now, Victor?

Right now, we are seeing innovative and differentiated pipeline.

Yes. Uh-huh. That's the pipeline.

Right. And if you could move it into presentation mode so that we don't see all the- That's what I have in front of me, yes.

Oh. But you don't have that, do you?